Efficacy and safety of treatments for metastatic castration ... - Nature
Dec 9, 2025 · Androgen deprivation therapy (ADT) has been the foundational treatment for management of patients with metastatic prostate cancer since the pioneering efforts of Huggins and Hodges [1].
FDA Grants Regular Approval to Rucaparib for Metastatic Castration ...
3 days ago · Last Updated: 12/18/2025 11:09:30 AM On December 17, the U.S. Food and Drug Administration (FDA) approved the PARP inhibitor rucaparib (Rubraca) for adults with deleterious …
TAM Plasticity under androgen deprivation therapy and PARP
2 days ago · Androgen deprivation therapy (ADT) and next-generation androgen receptor pathway inhibitors (ARPI) are increasingly combined with PARP inhibitors (PARPi) in metastatic prostate …
ASCO 2025: Transcriptome Classification of PTEN Inactivation to …
ASCO 2025 ancillary study of the STAMPEDE trials, Transcriptome classification of PTEN inactivation, survival benefit from docetaxel at start of androgen deprivation therapy (ADT), metastatic prostate …
Real-world use of androgen-deprivation therapy intensification for ...
Objective: To conduct a systematic literature review of real-world data (RWD) studies to summarise treatment patterns among men with metastatic hormone-sensitive prostate cancer (mHSPC). While …
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2 ...
Dec 13, 2025 · AKEEGA®plus prednisone was approved by the U.S. FDA in December 2025 under Priority Review for the treatment of patients with BRCA2-mutated metastatic castration-sensitive …
PSA at 6 to 12 Months of ADT Predicts Real-World Survival Outcomes …
Jul 10, 2025 · An absolute PSA level of 0.2 ng/mL or more at 6 to 12 months after initiation of androgen deprivation therapy (ADT) is prognostic for worse survival outcomes in patients with metastatic …
Tolmar Announces Expanded Indication for Rubraca® (rucaparib) First …
18 hours ago · Prostate cancer is the most diagnosed cancer in U.S. men, with an estimated 313,780 new cases diagnosed in 2025. 2 Approximately 10 to 20 percent of patients progress to castration …
Real-World Treatment Patterns and Survival in People With Metastatic ...
Oct 1, 2025 · Back-to-back androgen receptor pathway inhibitor use from metastatic hormone-sensitive prostate cancer (mHSPC) to metastatic castration-resistant prostate cancer (mCRPC) is common in …
Metformin might also mitigate the adverse metabolic efects of androgen-deprivation therapy (ADT). We hypothesised that metformin might improve survival in patients with metastatic hormone-sensitive …